Orthopoxviruses: Vaccinia (Smallpox Vaccine), Variola (Smallpox), Monkeypox, and Cowpox

Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases

Volumn 2, Issue , 2014, Pages 1694-1702.e3

  Petersen, Brett W ^a   Damon, Inger K ^a,b  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cowpox; Monkeypox; Orthopoxvirus; Poxvirus; Smallpox; Smallpox vaccine; Vaccinia; Variola; VIGIV

Indexed keywords

EID: 84924463485     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-4801-3.00135-1     Document Type: Chapter

References (238)

1. Moyer RW, Arif BM, Black DN, et al. Poxviridae. Virus Taxonomy: Seventh Report of the International Committee on Taxonomy of Viruses 2000, 137-157. Academic Press, San Diego. M.H.V. van Regenmortel, C.M. Fauquet, D.H.L. Bishop (Eds.).
2. Fenner F, Wittek R, Dumbell KR The Orthopoxviruses 1989, Academic Press, Boston.
3. Moss B Poxviridae: the viruses and their replication. Fields' Virology 2007, 2905-2947. Lippincott Williams & Wilkins, Philadelphia. 5th ed. B.N. Fields, D.M. Knipe, P.M. Howley (Eds.).
4. Damon IK Poxviruses. Fields' Virology 2007, 2947-2976. Lippincott Williams & Wilkins, Philadelphia. 5th ed. B.N. Fields, D.M. Knipe, P.M. Howley (Eds.).
5. Poxviruses: Advances in Infectious Diseases 2007, Birkhauser, Boston. A.A. Mercer, A. Schmidt, O. Weber (Eds.).
6. Verardi PH, Titong A, Hagen CJ A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication. Hum Vacc Immunother 2012, 8:961-970.
7. Centers for Disease Control and Prevention, Department of Health and Human Services Possession, use, and transfer of select agents and toxins. Final rule. Fed Regist 2008, 73:61363-61366.
8. Damon IK Poxviruses. Manual of Clinical Microbiology 2007, 1631-1640. American Society for Microbiology Press, Washington, DC. 9th ed. P.R. Murray, E.J. Baron, J.H. Jorgensen (Eds.).
9. Nakano JH Poxviruses. Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections 1979, 257-308. American Public Health Association, Washington, DC. 5th ed. E.H. Lennette, N.J. Schmidt (Eds.).
10. Smith GL, Vanderplasschen A, Law M The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 2002, 83:2915-2931.
11. Smith GL Vaccinia virus morphogenesis and dissemination. Trends Microbiol 2008, 16:472-479.
12. Moss B Poxvirus entry and membrane fusion. Virology 2006, 344:48-54.
13. Moss B Poxvirus cell entry: how many proteins does it take?. Viruses 2012, 4:688-707.
14. Payne LG Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia virus. J Gen Virol 1980, 50:89-100.
15. Fenner F, Wittek R, Dumbell KR The Pathogenesis, Pathology, and Immunology of Orthopoxvirus Infections. The Orthopoxviruses 1989, Academic Press, Boston.
16. Roberts JA Histopathogenesis of mousepox, I. Respiratory infection. Br J Exp Pathol 1962, 43:451-461.
17. Bedson HS, Duckworth MJ Rabbitpox: an experimental study of the pathways of infection in rabbits. J Pathol Bacteriol 1963, 85:1-20.
18. Buller RM, Palumbo GJ Poxvirus pathogenesis. Microbiol Rev 1991, 55:80-122.
19. Zaucha GM, Jahrling PB, Geisbert TW, et al. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest 2001, 81:1581-1600.
20. Hutson CL, Olson VA, Carroll DS, et al. A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus. J Gen Virol 2009, 90:323-333.
21. Smith S, Kotwal GJ Immune response to poxvirus infections in various animals. Crit Rev Microbiol 2002, 28:149-185.
22. Martinez MJ, Bray M, Huggins JW A mouse model of aerosol-transmitted orthopoxviral disease. Arch Pathol Lab Med 2000, 124:362-377.
23. Bray M, Martinez M, Smee DF, et al. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis 2000, 181:10-19.
24. Smith SK, Self J, Weiss S, et al. Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus. J Virol 2011, 85:9176-9187.
25. Karupiah G, Fredrickson TN, Holmes KL, et al. Importance of interferons in recovery from mousepox. J Virol 1993, 63:4214-4226.
26. Wakamiya N, Okada N, Wang YL, et al. Tumor cells treated with vaccinia virus can activate the alternate pathway of mouse complement. Jpn J Cancer Res 1989, 80:765-770.
27. West BC, Eschete ML, Cox ME, et al. Neutrophil uptake of vaccinia virus in vitro. J Infect Dis 1987, 156:597-606.
28. Jones JF Interactions between human neutrophils and vaccinia virus: induction of oxidative metabolism and virus inactivation. Pediatr Res 1982, 16:525-529.
29. Doherty PC, Korngold R Characteristics of poxvirus-induced meningitis: virus-specific and non-specific cytotoxic effectors in the inflammatory exudates. Scand J Immunol 1983, 18:1-7.
30. Blanden RV, Gardner ID The cell-mediated response to ectromelia virus infection, I. Kinetics and characteristics of the primary effector T cell response in vivo. Cell Immunol 1976, 22:271-282.
31. Rubins KH, Hensley LE, Jahrling PB, et al. The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. Proc Natl Acad Sci U S A 2004, 101:15190-15195.
32. Rubins KH, Hensley LE, Relman DA, Brown PO Stunned silence: gene expression programs in human cells infected with monkeypox or vaccinia virus. PloS One 2011, 6:e15615.
33. Seet BT, Johnston JB, Brunetti CR, et al. Poxviruses and immune evasion. Annu Rev Immunol 2003, 21:377-423.
34. Smith GL, Symons JA, Khanna A, et al. Vaccinia virus immune evasion. Immunol Rev 1997, 159:137-154.
35. Johnston JB, MacFadden G Poxvirus immunomodulatory strategies: current perspectives. J Virol 2003, 77:6093-6100.
36. MacNeil A, Reynolds MG, Damon IK Risks associated with vaccinia virus in the laboratory. Virology 2009, 385:1-4.
37. Carroll DS, Emerson GL, Li Y, et al. Chasing Jenner's vaccine: revisiting cowpox virus classification. PloS One 2011, 6:e23086.
38. Cono J, Casey CG, Bell D Smallpox vaccination and adverse reactions: guidance for clinicians. MMWR Recomm Rep 2003, 52:1-28.
39. Arenstein AW, Rubins K, Relman DA Smallpox vaccination. N Engl J Med 2003, 348:1925.
40. Vaccinia Immune Globulin Intravenous (Human) [package insert] 2010, Cangene Corporation, Winnipeg, Manitoba, Canada.
41. World Health Organization Expert Committee on Smallpox Eradication Second report. WHO Tech Rep Ser 1972, 493:1-64.
42. Hammarlund E, Lewis MW, Hansen SG, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003, 9:1131-1137.
43. Taub DD, Ershler WB, Janowski M, et al. Immunity from smallpox vaccine persists for decades: a longitudinal study. Am J Med 2008, 121:1058-1064.
44. Karem KL, Reynolds M, Hughes C, et al. Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. Clin Vaccine Immunol 2007, 14:1318-1327.
45. Croft DR, Sotir MJ, Williams CJ, et al. Occupational risks during a monkeypox outbreak, Wisconsin, 2003. Emerg Infect Dis 2007, 13:1150-1157.
46. Mack TM Smallpox in Europe, 1950-1971. J Infect Dis 1972, 125:161-169.
47. Hanna W, Baxby B Studies in small-pox and vaccination. 1913. Rev Med Virol 2002, 12:201-209.
48. Massoudi MS, Barker L, Schwartz B Effectiveness of postexposure vaccination for the prevention of smallpox: results of a Delphi analysis. J Infect Dis 2003, 188:973-976.
49. Rao AR, Jacob ES, Kamalakshi S, et al. Epidemiological studies in smallpox: a study of intrafamilial transmission in a series of 254 infected families. Indian J Med Res 1968, 56:1826-1854.
50. Heiner GG, Fatima N, McCrumb FR A study of intrafamilial transmission of smallpox. Am J Epidemiol 1974, 99:316-326.
51. Sommer A The 1972 smallpox outbreak in Khulna Municipality, Bangladesh, II. Effectiveness of surveillance and containment in urban epidemic control. Am J Epidemiol 1974, 99:303-313.
52. Fenner F Studies in mousepox: infectious ectromelia of mice, IV. Quantitative investigations on the spread of virus through the host in actively and passively immunized animals. Aust J Exp Biol Med 1947, 27:1-18.
53. Mack TM, Noble J, Thomas DB A prospective study of serum antibody and protection against smallpox. Am J Trop Med Hyg 1972, 21:214-218.
54. Sarkar JK, Mitra AC, Mukherjee MK The minimum protective levels of antibodies in smallpox. Bull World Health Organ 1975, 52:307-311.
55. McClain DJ, Harrison S, Yeager CL, et al. Immunologic responses to vaccinia vaccines administered by different parenteral routes. J Infect Dis 1997, 175:756-763.
56. Ennis FA, Cruz J, Demkowicz WE, et al. Primary induction of human CD8+ cytotoxic T lymphocytes and interferon-γ-producing T cells after smallpox vaccination. J Infect Dis 2002, 185:1657-1659.
57. Demkowicz WE, Littaua RA, Wang J, et al. Human cytotoxic T-cell memory: long-lived responses to vaccinia virus. J Virol 1996, 70:2627-2631.
58. Hammersland E, Lewis MW, Hansen SG, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003, 9:1131-1137.
59. Hsieh SM, Pan SC, Chen SY, et al. Age distribution for T cell reactivity to vaccinia virus in a healthy population. Clin Infect Dis 2003, 38:86-89.
60. Baruch E, Roth Y, Winder A, et al. The persistence of neutralizing antibodies after revaccination against smallpox. J Infect Dis 1990, 161:446-448.
61. Frey SE, Newman FK, Yan L, et al. Response to smallpox vaccine in persons immunized in the distant past. JAMA 2003, 289:3295-3296.
62. Bray M, Wright M Progressive vaccinia. Clin Infect Dis 2003, 36:766-774.
63. Sliva K, Schnierle B From actually toxic to highly specific-novel drugs against poxviruses. Virology 2007, 4:8.
64. Centers for Disease Control and Prevention Progressive vaccinia in a military smallpox vaccinee-United States, 2009. MMWR Morb Mortal Wkly Rep 2009, 58:532-536.
65. Lederman ER, Davidson W, Groff HL, et al. Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J Infect Dis 2012, 206:1372-1385.
66. Neff JM, Lane MM, Pert J, et al. Complications of smallpox vaccination, I. National survey in the United States, 1963. N Engl J Med 1967, 276:125-132.
67. Lane JM, Ruben FL, Neff JM, et al. Complications of smallpox vaccination, 1968: national surveillance in the United States. N Engl J Med 1969, 281:1201-1208.
68. Lane JM, Ruben F, Neff JM, et al. Complications of smallpox vaccination, 1968: results of statewide surveys. J Infect Dis 1970, 122:303-309.
69. Feery BJ Adverse reactions after smallpox vaccination. Med J Aust 1977, 2:41-42.
70. Fulginetti V, Kempe C, Hathaway W, et al. Progressive vaccinia in immunologically deficient individuals. Birth Defects Orig Artic Ser 1968, 4:129-145.
71. Goldstein J, Neff J, Lane J, et al. Smallpox vaccination reactions, prophylaxis and therapy of complications. Pediatrics 1975, 55:342-347.
72. Keidan SE, McCarthy K, Haworth JC Fatal generalized vaccinia with failure of antibody production and absence of serum gamma globulin. Arch Dis Child 1953, 28:110-116.
73. Copeman PWM, Wallace HJ Eczema vaccinatum. BMJ 1964, 5414:906-908.
74. Rachelefsky GS, Opelz G, Mickey R Defective T cell function in atopic dermatitis. J Allergy Clin Immunol 1976, 57:569-576.
75. Kempe CH Studies on smallpox and complications of smallpox vaccination. Pediatrics 1960, 26:176-189.
76. Vora S, Damon I, Fulginiti V, et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 2008, 46:1555-1561.
77. Miller JR, Cirino NM, Philbin EF Generalized vaccinia 2 days after smallpox revaccination. Emerg Infect Dis 2003, 12:1649-1650.
78. Lewis FS, Norton SA, Bradshaw RD, et al. Analysis of cases reported as generalized vaccinia during the US military smallpox vaccination program, December 2002 to December 2004. J Am Acad Dermatol 2006, 55:23-31.
79. Fenner F, Henderson DA, Arita I, et al. Smallpox and Its Eradication 1988, World Health Organization, Geneva.
80. Sejvar JJ, Labutta RJ, Chapman LE, et al. Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004. JAMA 2005, 294:2744-2750.
81. Kurata T, Aoyama Y, Kitamura T Demonstration of vaccinia virus antigen in brains of postvaccinal encephalitis cases. Jpn J Med Sci Bio 1977, 30:137-147.
82. Gurvich EB, Vilesova IS Vaccinia virus in postvaccinal encephalitis. Acta Virol 1983, 27:154-159.
83. De Vries E Postvaccinial Perivenous Encephalitis 1960, Elsevier, Amsterdam.
84. Tenembaum S, Nestor C, Fejerman N Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology 2002, 59:1224-1231.
85. Gurvich E, Vilesova I Vaccinia virus in postvaccinial encephalitis. Acta Virol 1983, 27:154-159.
86. Van Dam CN, Syed S, Eron JJ, et al. Severe postvaccinia encephalitis with acute disseminated encephalomyelitis: recovery with early intravenous immunoglobulin, high-dose steroids, and vaccinia immunoglobulin. Clin Infect Dis 2009, 48:e47-e49.
87. Melekhin VV, Karem KL, Damon IK, et al. Encephalitis after secondary smallpox vaccination. Clin Infect Dis 2009, 48:e1-e2.
88. Miravalle A, Roos KL Encephalitis complicating smallpox vaccination. Arch Neurol 2003, 60:925-928.
89. Ruben FL, Lane JM Ocular vaccinia: an epidemiologic analysis of 348 cases. Arch Ophthalmol 1970, 84:45-48.
90. Kern E In vitro activity of potential anti-poxvirus agents. Antivir Res 2003, 57:35-40.
91. Karjalainen J, Heikkila J, Nieminen MS, et al. Etiology of mild acute infectious myocarditis. Acta Med Scand 1983, 213:65-73.
92. Helle EJ, Koskenvuo K, Heikkila J, et al. Myocardial complications of immunisations. Ann Clin Res 1978, 10:280-287.
93. Halsell JS, Riddle JR, Atwood JE, et al. Myopericarditis following smallpox vaccination among vaccinia-na�ve U.S. military personnel. JAMA 2003, 289:3283-3289.
94. Greenberg RN, Kennedy JS ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin Investig Drugs 2008, 17:555-564.
95. Mora LF, Khan AH, Sperling LS Cardiac complications after smallpox vaccination. South Med J 2009, 102:615-619.
96. Morgan J, Roper MH, Sperling L, et al. Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States, January-October 2003. Clin Infect Dis 2008, 46(suppl 3):S242-S250.
97. Grabenstein JD, Winkenwerder W U.S. military smallpox vaccination program experience. JAMA 2003, 289:3278-3282.
98. Centers for Disease Control and Prevention Supplemental recommendations on adverse events following smallpox vaccine in the pre-event vaccination program: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2003, 52:282-284. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5213a5.htm.
99. Cardiac adverse events following smallpox vaccination-United States, 2003. MMWR Morb Mortal Wkly Rep 2003, 52:248-250.
100. Macadam DB, Whitaker W Cardiac complication after vaccination for smallpox. BMJ 1962, 5312:1099-1100.
101. Ahlborg B, Linroth K, Nordgren B ECG-changes without subjective symptoms after smallpox vaccination of military personnel. Acta Med Scand 1966, S464:127-134.
102. Centers for Disease Control and Prevention Update: adverse events following civilian smallpox vaccination-United States, 2003. MMWR Morb Mortal Wkly Rep 2003, 52:819-820.
103. Update on cardiac and other adverse events following civilian smallpox vaccination-United States, 2003. MMWR Morb Mortal Wkly Rep 2003, 52:639-642.
104. Talbot TR, Bredenberg HK, Smith M, et al. Focal and generalized folliculitis following smallpox vaccination among vaccinia-na�ve recipients. JAMA 2003, 289:3290-3294.
105. Wharton M, Strikas RA, Harpaz R, et al. Recommendations for using smallpox vaccine in a pre-event vaccination program. MMWR Recomm Rep 2003, 52:1-16.
106. Dumbell KR, Richardson M Virological investigations of specimens from buffaloes affected by buffalopox in Maharashtra State, India between 1985 and 1987. Arch Virol 1993, 128:257-267.
107. Mathew T Advances in Medical and Veterinary Virology, Immunology and Epidemiology: Cultivation and Immunological Studies on Pox Groups of Viruses with Special Reference to Buffalo Pox Virus 1987, India: Thajema Publishers, New Delhi.
108. Zafar A, Swanepoel R, Hewson R, et al. Nosocomial buffalopox-virus infection, Karachi, Pakistan. Emerg Infect Dis 2007, 13:902-904.
109. Damaso CRA, Esposito JJ, Condit RC, et al. An emergent poxvirus from humans and cattle in Rio de Janeiro state: Cantagalo virus may derive from Brazilian smallpox vaccine. Virology 2000, 277:439-449.
110. Schatzmayr HG, Sampaio de Lemos ER, Mazur C, et al. Detection of poxvirus in cattle associated with human cases in the state of Rio de Janeiro: preliminary report. Mem Inst Oswaldo Cruz 2000, 95:625-627.
111. Trindade GS, Guedes MI, Drumond BP, et al. Zoonotic vaccinia virus: clinical and immunological characteristics in a naturally infected patient. Clin Infect Dis 2009, 48:e37-e40.
112. Trindade GS, Lobato ZI, Drumond BP, et al. Short report: isolation of two vaccinia virus strains from a single bovine vaccinia outbreak in rural area from Brazil: implications on the emergence of zoonotic orthopoxviruses. Am J Trop Med Hyg 2006, 75:486-490.
113. Leite JA, Drumond BP, Trindade GS, et al. Passatempo virus, a vaccinia virus strain, Brazil. Emerg Infect Dis 2005, 11:1935-1938.
114. Trindade GS, Emerson GL, Carroll DS, et al. Brazilian vaccinia viruses and their origins. Emerg Infect Dis 2007, 13:965-972.
115. da Fonseca FG, Trindade GS, Silva RL, et al. Characterization of a vaccinia-like virus isolated in a Brazilian forest. J Gen Virol 2002, 83:223-228.
116. Rupprecht CE, Blass L, Smith K, et al. Human infection due to recombinant vaccinia-rabies glycoprotein virus. N Engl J Med 2001, 345:582-586.
117. Centers for Disease Control and Prevention Human vaccinia infection after contact with a raccoon rabies vaccine bait-Pennsylvania, 2009. MMWR Morb Mortal Wkly Rep 2009, 58:1204-1207.
118. Milton DK What was the primary mode of smallpox transmission? Implications for biodefense. Front Cellular Infect Microbiol 2012, 2:150.
119. Breman JA, Henderson DA Diagnosis and management of smallpox. N Engl J Med 2002, 346:1300-1308.
120. Dixon CW Differential Diagnosis, Laboratory Diagnosis, Post-mortem Appearance in Smallpox 1962, Churchill, London.
121. Bremen JG Monkeypox: an emerging infection for humans?. Emerging Infections 2000, 45-67. American Society for Microbiology Press, Washington, DC. 4th ed. W.M. Scheld, W.A. Craig, J.M. Hughes (Eds.).
122. Jezek Z, Fenner F Human monkeypox. Monogr Virol 1988, 17:1-140.
123. Damon IK Status of human monkeypox: clinical disease, epidemiology and research. Vaccine 2011, 29(suppl 4):D54-D59.
124. Hutin YJF, Williams RJ, Malfait P, et al. Outbreak of human monkeypox in the Democratic Republic of Congo, 1996-1997. Emerg Infect Dis 2000, 7:434-438.
125. Heymann DL, Szczeniowski M, Esteves K Re-emergence of monkeypox in Africa: a review of the past six years. Br Med Bull 1998, 54:693-702.
126. Khodacevich L, Jezek Z, Messinger D Monkeypox virus: ecology and public health significance. Bull World Health Organ 1988, 66:747-752.
127. Update: Multistate outbreak of monkeypox-Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep 2003, 52:642-646.
128. Anderson M, Frenkel LD, Homann S, et al. A case of severe monkeypox virus disease in an American child: emerging infections and changing professional values. Pediatr Infect Dis J 2003, 22:1093-1096.
129. Reed KD, Melski JW, Graham MB, et al. The detection of monkeypox in humans in the western hemisphere. N Engl J Med 2004, 350:342-350.
130. Reynolds MG, Davidson WB, Curns AT, et al. Spectrum of infection and risk factors for human monkeypox, United States, 2003. Emerg Infect Dis 2007, 13:1332-1339.
131. Likos AM, Sammons SA, Olson VA, et al. A tale of two clades: monkeypox viruses. J Gen Virol 2005, 86:2661-2672.
132. Chen N, Li G, Liszewski MK, et al. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology 2005, 340:46-63.
133. Olson VA, Carroll DS, Abel JA, et al. A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo Basin strains of monkeypox virus. J Gen Virol 2009, 90:323-333.
134. Ibrahim MS, Kulesh D, Saleh SS, et al. Real-time PCR assay to detect smallpox virus. J Clin Microbiol 2003, 41:3385-3389.
135. Meyer H, Ropp SL, Esposito JJ Gene for A-type inclusion body protein is useful for a polymerase chain reaction assay to differentiate orthopoxviruses. J Virol Methods 1997, 64:217-222.
136. Meyer H, Ropp SL, Esposito JJ Poxviruses. Methods in Molecular Biology: Diagnostic Virology Protocols, 1998 1998, 199-211. Humana Press, Totowa, NJ. A. Warnes, J. Stephenson (Eds.).
137. Ropp SL, Jin Q, Knight JC, et al. PCR strategy for identification and differentiation of smallpox and other orthopoxviruses. J Clin Microbiol 1995, 33:2069-2076.
138. Loparev VN, Massung RF, Esposito JJ, et al. Detection and differentiation of Old World orthopoxviruses: restriction length polymorphism of the crmB gene region. J Clin Microbiol 2001, 39:94-100.
139. Li Y, Olson VA, Laue T, et al. Detection of monkeypox virus with real-time PCR assays. J Clin Virol 2006, 36:194-203.
140. Karem KL, Reynolds M, Braden Z, et al. Characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak. Clin Diagn Lab Immunol 2005, 12:867-872.
141. Learned LA, Reynolds MG, Wassa DW, et al. Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003. Am J Trop Med Hyg 2005, 73:428-434.
142. Meyer H, Perrichot M, Stemmler P, et al. Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001. J Clin Microbiol 2002, 40:2919-2921.
143. Rimoin AW, Kisalu N, Kebela-Ilunga B, et al. Endemic human monkeypox, Democratic Republic of Congo, 2001-2004. Emerg Infect Dis 2007, 13:934-937.
144. Lederman ER, Reynolds MG, Karem K, et al. Prevalence of antibodies against orthopoxviruses among residents of Likouala region, Republic of Congo: evidence for monkeypox virus exposure. Am J Trop Med Hyg 2007, 77:1150-1156.
145. Douglas NJ, Dumbell KR Independent evolution of monkeypox and variola viruses. J Virol 1992, 66:7565-7567.
146. Shchelkunov SN, Totmenin AV, Safronov PF, et al. Analysis of the monkeypox genome. Virology 2002, 297:172-194.
147. McCollum AM, Austin C, Nawrocki J, et al. Investigation of the first laboratory-acquired human cowpox virus infection in the United States. J Infect Dis 2012, 206:63-68.
148. Savaser DJ, Tolia VM, Witucki PJ Cowpox: what do a dairymaid and a lab technician have in common?. J Emerg Med 2012, 44:189-190.
149. Baxby D Poxvirus infections in domestic animals. Virus Diseases in Laboratory and Captive Animals 1988, 17-35. Nijhoff, Boston. G. Darai (Ed.).
150. Baxby D, Bennett M, Getty B Human cowpox 1969-93: a review based on 54 cases. Br J Dermatol 1994, 131:598-607.
151. Bennett M, Gaskell CJ, Baxby D, et al. Feline cowpox infection. J Small Anim Pract 1990, 31:167-173.
152. Bennett M, Crouch AJ, Begon M, et al. Cowpox in British voles and mice. J Comp Pathol 1997, 116:35-44.
153. Pelkonen PM, Tarvainen K, Hynninen A, et al. Cowpox with severe generalized eruption, Finland. Emerg Infect Dis 2003, 9:1458-1461.
154. Dubois ME, Slifka MK Retrospective analysis of monkeypox infection. Emerg Infect Dis 2008, 14:592-599.
155. Neyts J, De Clerq E Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives. Antiviral Res 2003, 57:25-33.
156. LeDuc J, Damon I, Meegan J, et al. Smallpox research activities: U.S. interagency collaboration. Emerg Infect Dis 2002, 8:742-745.
157. Keith KA, Hitchcock MJ, Lee WA, et al. Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication. Antimicrob Agents Chemother 2003, 47:2193-2198.
158. Bauer DJ The antiviral and synergistic actions of isatin thiosemicarbazone and certain phenoxypyrimidines in vaccinia infection in mice. Br J Exp Pathol 1955, 36:105-114.
159. Rao M, McFadzean J, Squires S The laboratory and clinical assessment of an iso-thiazole thiosemicarbazone (M&B 7714) against pox viruses. Ann N Y Acad Sci 1965, 130:118-127.
160. Heiner GG, Fatima N, Russell PK, et al. Field trials of methisazone as a prophylactic agent against smallpox. Am J Epidemiol 1971, 94:435-449.
161. Neyts J, De Clerq ED Therapy and short term prophylaxis of poxvirus infections: historical background and perspectives. Antiviral Res 2003, 57:25-33.
162. Smee DF, Sidwell RW A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res 2003, 57:41-52.
163. Neyts J, Verbeken E, De Clerq E Effect of 5-iodo-2'-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice. Antimicrob Agents Chemother 2002, 46:2842-2847.
164. Hyndiuk R, Seideman S, Leibsohn JM Treatment of vaccinial dermatitis with trifluorothymidine. Arch Ophthalmol 1976, 94:1785-1786.
165. Hyndiuk R, Okumoto M, Damiano R, et al. Treatment of vaccinial keratitis with vidarabine. Arch Ophthalmol 1976, 94:1363-1364.
166. Kaufman H, Nesburn A, Maloney E Cure of vaccinia infection by 5-iodo-2-deoxyuridine. Virology 1962, 18:567-569.
167. Quenelle DC, Collins DJ, Kern ER Efficacy of multiple or single dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob Agents Chemother 2003, 47:3275-3280.
168. Winegarden KL, Ciesla SL, Aldern KA, et al. Oral pharmacokinetics and preliminary toxicology of 1-O-hexadecyloxypropylcidofovir in mice. Abstracts of the 15th International Conference on Antiviral Research, Prague, Czech Republic, March 17-21, 2002. Antiviral Res 2002, 53:A67.
169. Parker S, Touchette E, Oberle C, et al. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res 2008, 77:39-49.
170. Smee D, Bailey K, Sidwell R Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug. Antiviral Res 2002, 54:113-120.
171. Neyts J, De Clerq E Efficacy of 2-amino-7-(1,3-dihydroxy-2-propoxymethyl) purine for treatment of vaccinia virus (orthopoxvirus) infections in mice. Antimicrob Agents Chemother 2002, 45:84-87.
172. Yang G, Pevear DC, Davies MH, et al. An orally bio�available antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol 2005, 79:13139-13149.
173. Smith SK, Olson VA, Karem KL, et al. ST246 in vitro efficacy against smallpox and monkeypox. Antimicrob Agents Chemother 2008, 53:1007-1012.
174. Duraffour S, Snoeck R, de Vos R, et al. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir Ther 2007, 12:1205-1216.
175. Nalca A, Hatkin JM, Garza NL, et al. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res 2008, 79:121-127.
176. Sbrana E, Jordan R, Hruby DE, et al. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am J Trop Med Hyg 2007, 76:768-773.
177. Quenelle DC, Buller RM, Parker S, et al. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother 2007, 51:689-695.
178. Quenelle DC, Prichard MN, Keith KA, et al. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother 2007, 51:4118-4124.
179. Baker RO, Bray M, Huggins JW Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res 2003, 57:13-23.
180. Sidwell R, Allen L, Khare G, et al. Effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole, ICN 1229) on herpes and vaccinia keratitis and encephalitis in laboratory animals. Antimicrob Agents Chemother 1973, 3:242-246.
181. De Clerq E, Luczak M, Shugar D, et al. Effect of cytosine arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatode-oxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus. Proc Soc Exp Biol Med 1976, 151:487-490.
182. Kesson A, Ferguson J, Rawlinson W, et al. Progressive vaccinia treated with ribavirin and vaccinia immune globulin. Clin Infect Dis 1997, 25:911-914.
183. Newsome TP, Weisswange I, Frischknecht F, et al. Abl collaborates with Src family kinases to stimulate actin-based motility of vaccinia virus. Cell Microbiol 2006, 8:233-241.
184. Reeves PM, Bommarius B, Lebeis S, et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med 2005, 11:731-739.
185. Yang H, Kim SK, Kim M, et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest 2005, 115:379-387.
186. Bray M Pathogenesis and potential antiviral therapy of com�plications of smallpox vaccination. Antiviral Res 2003, 58:101-114.
187. Smee DF, Smee DF Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother 2008, 19:115-124.
188. De Clercq E Emerging antiviral drugs. Expert Opin Emerg Drugs 2008, 13:393-416.
189. Baker RO, Bray M, Huggins JW Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res 2003, 57:13-23.
190. Arndt W, Mitnik C, Denzler KL, et al. In vitro characterization of a nineteenth-century therapy for smallpox. PloS One 2012, 7:e32610.
191. Moss B Poxviridae: the viruses and their replication. Fields' Virology 2007, 2905-2947. Lippincott Williams & Wilkins, Philadelphia. 5th ed. B.N. Fields, D.M. Knipe, P.M. Howley (Eds.).
192. Damon IK Poxviruses. Fields' Virology 2007, 2947-2976. Lippincott Williams & Wilkins, Philadelphia. 5th ed. B.N. Fields, D.M. Knipe, P.M. Howley (Eds.).
193. Verardi PH, Titong A, Hagen CJ A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication. Hum Vacc Immunother 2012, 8:961-970.
194. Damon IK Poxviruses. Manual of Clinical Microbiology 2007, 1631-1640. American Society for Microbiology Press, Washington, DC. 9th ed. P.R. Murray, E.J. Baron, J.H. Jorgensen (Eds.).
195. Moss B Poxvirus entry and membrane fusion. Virology 2006, 344:48-54.
196. Moss B Poxvirus cell entry: how many proteins does it take?. Viruses 2012, 4:688-707.
197. Seet BT, Johnston JB, Brunetti CR, et al. Poxviruses and immune evasion. Annu Rev Immunol 2003, 21:377-423.
198. MacNeil A, Reynolds MG, Damon IK Risks associated with vaccinia virus in the laboratory. Virology 2009, 385:1-4.
199. Carroll DS, Emerson GL, Li Y, et al. Chasing Jenner's vaccine: revisiting cowpox virus classification. PloS One 2011, 6:e23086.
200. Cono J, Casey CG, Bell D Smallpox vaccination and adverse reactions: guidance for clinicians. MMWR Recomm Rep 2003, 52:1-28.
201. Taub DD, Ershler WB, Janowski M, et al. Immunity from smallpox vaccine persists for decades: a longitudinal study. Am J Med 2008, 121:1058-1064.
202. Karem KL, Reynolds M, Hughes C, et al. Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. Clin Vaccine Immunol 2007, 14:1318-1327.
203. Massoudi MS, Barker L, Schwartz B Effectiveness of postexposure vaccination for the prevention of smallpox: results of a Delphi analysis. J Infect Dis 2003, 188:973-976.
204. Rao AR, Jacob ES, Kamalakshi S, et al. Epidemiological studies in smallpox: a study of intrafamilial transmission in a series of 254 infected families. Indian J Med Res 1968, 56:1826-1854.
205. Mack TM, Noble J, Thomas DB A prospective study of serum antibody and protection against smallpox. Am J Trop Med Hyg 1972, 21:214-218.
206. Sarkar JK, Mitra AC, Mukherjee MK The minimum protective levels of antibodies in smallpox. Bull World Health Organ 1975, 52:307-311.
207. Bray M, Wright M Progressive vaccinia. Clin Infect Dis 2003, 36:766-774.
208. Sliva K, Schnierle B From actually toxic to highly specific-novel drugs against poxviruses. Virology 2007, 4:8.
209. Lederman ER, Davidson W, Groff HL, et al. Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J Infect Dis 2012, 206:1372-1385.
210. Neff JM, Lane MM, Pert J, et al. Complications of smallpox vaccination, I. National survey in the United States, 1963. N Engl J Med 1967, 276:125-132.
211. Lane JM, Ruben FL, Neff JM, et al. Complications of smallpox vaccination, 1968: national surveillance in the United States. N Engl J Med 1969, 281:1201-1208.
212. Lane JM, Ruben F, Neff JM, et al. Complications of smallpox vaccination, 1968: results of statewide surveys. J Infect Dis 1970, 122:303-309.
213. Kempe CH Studies on smallpox and complications of smallpox vaccination. Pediatrics 1960, 26:176-189.
214. Lewis FS, Norton SA, Bradshaw RD, et al. Analysis of cases reported as generalized vaccinia during the US military smallpox vaccination program, December 2002 to December 2004. J Am Acad Dermatol 2006, 55:23-31.
215. Fenner F, Henderson DA, Arita I, et al. Smallpox and Its Eradication 1988, World Health Organization, Geneva.
216. Van Dam CN, Syed S, Eron JJ, et al. Severe postvaccinia encephalitis with acute disseminated encephalomyelitis: recovery with early intravenous immunoglobulin, high-dose steroids, and vaccinia immunoglobulin. Clin Infect Dis 2009, 48:e47-e49.
217. Melekhin VV, Karem KL, Damon IK, et al. Encephalitis after secondary smallpox vaccination. Clin Infect Dis 2009, 48:e1-e2.
218. Halsell JS, Riddle JR, Atwood JE, et al. Myopericarditis following smallpox vaccination among vaccinia-na�ve U.S. military personnel. JAMA 2003, 289:3283-3289.
219. Greenberg RN, Kennedy JS ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin Investig Drugs 2008, 17:555-564.
220. Mora LF, Khan AH, Sperling LS Cardiac complications after smallpox vaccination. South Med J 2009, 102:615-619.
221. Morgan J, Roper MH, Sperling L, et al. Myocarditis, pericarditis, and dilated cardiomyopathy after smallpox vaccination among civilians in the United States, January-October 2003. Clin Infect Dis 2008, 46(suppl 3):S242-S250.
222. Grabenstein JD, Winkenwerder W U.S. military smallpox vaccination program experience. JAMA 2003, 289:3278-3282.
223. Wharton M, Strikas RA, Harpaz R, et al. Recommendations for using smallpox vaccine in a pre-event vaccination program. MMWR Recomm Rep 2003, 52:1-16.
224. Damaso CRA, Esposito JJ, Condit RC, et al. An emergent poxvirus from humans and cattle in Rio de Janeiro state: Cantagalo virus may derive from Brazilian smallpox vaccine. Virology 2000, 277:439-449.
225. Trindade GS, Guedes MI, Drumond BP, et al. Zoonotic vaccinia virus: clinical and immunological characteristics in a naturally infected patient. Clin Infect Dis 2009, 48:e37-e40.
226. Rupprecht CE, Blass L, Smith K, et al. Human infection due to recombinant vaccinia-rabies glycoprotein virus. N Engl J Med 2001, 345:582-586.
227. Centers for Disease Control and Prevention Human vaccinia infection after contact with a raccoon rabies vaccine bait-Pennsylvania, 2009. MMWR Morb Mortal Wkly Rep 2009, 58:1204-1207.
228. Breman JA, Henderson DA Diagnosis and management of smallpox. N Engl J Med 2002, 346:1300-1308.
229. Bremen JG Monkeypox: an emerging infection for humans?. Emerging Infections 2000, 45-67. American Society for Microbiology Press, Washington, DC. 4th ed. W.M. Scheld, W.A. Craig, J.M. Hughes (Eds.).
230. Damon IK Status of human monkeypox: clinical disease, epidemiology and research. Vaccine 2011, 29(suppl 4):D54-D59.
231. Reed KD, Melski JW, Graham MB, et al. The detection of monkeypox in humans in the western hemisphere. N Engl J Med 2004, 350:342-350.
232. Likos AM, Sammons SA, Olson VA, et al. A tale of two clades: monkeypox viruses. J Gen Virol 2005, 86:2661-2672.
233. Baxby D, Bennett M, Getty B Human cowpox 1969-93: a review based on 54 cases. Br J Dermatol 1994, 131:598-607.
234. Neyts J, De Clerq E Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives. Antiviral Res 2003, 57:25-33.
235. Quenelle DC, Prichard MN, Keith KA, et al. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother 2007, 51:4118-4124.
236. Reeves PM, Bommarius B, Lebeis S, et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med 2005, 11:731-739.
237. Smee DF Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother 2008, 19:115-124.
238. De Clercq E Emerging antiviral drugs. Expert Opin Emerg Drugs 2008, 13:393-416.